New Zealand’s PHARMAC Funds J&J’s Concerta, Topamax: Australia/New Zealand Regulatory Roundup

PERTH, Australia - New Zealand's Pharmaceutical Management Agency will now fund Johnson & Johnson's Concerta (methylphenidate extended release) for the treatment of attention deficit hyperactivity disorder, beginning Sept. 1